
    
      The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum
      tolerated dose of CGX1321 when administered to subjects with advanced solid tumors.

      The purpose of the Dose Expansion Phase, Roll-over Cohort and Phase 1b is to continue to
      examine the safety and confirm the final Phase 2 dose of CGX1321 alone in subjects with
      advanced GI tumors (Dose Expansion Phase) and evaluate the safety and tolerability of CGX1321
      in combination with pembrolizumab (Phase 1b and Roll-over Cohort)
    
  